Table 2. Results of Mixed Treatment Comparison.
| Treatment | Rank (95% CrI) | Probability best treatment (%) | Mean weight change compared with placebo (kg) (95% CrI) |
|---|---|---|---|
| Exenatide 2mg | 3 (1, 6) | 26.04 | -1.62 (-2.95, -0.30) |
| Liraglutide 1.8mg | 3 (1, 6) | 19.76 | -1.51 (-2.67, -0.37) |
| Exenatide 20μg | 4 (1, 6) | 6.45 | -1.37 (-2.22, -0.52) |
| Liraglutide 1.2mg | 5 (1, 8) | 5.83 | -1.01 (-2.41, 0.38) |
| Sitagliptin | 5 (1, 10) | 14.72 | -0.88 (-3.31, 1.63) |
| Metformin | 5 (1, 9) | 8.54 | -0.95 (-2.75, 0.86) |
| Insulin Detemir + Liraglutide 1.8 mg | 6 (1, 11) | 14.17 | -0.71 (-3.33, 1.99) |
| Placebo | 8 (5, 10) | 0.02 | — |
| Exenatide 20μg + Rosiglitazone | 8 (1, 13) | 4.45 | 0.25 (-2.54, 3.00) |
| Insulin Detemir | 11 (8, 15) | 0.01 | 1.85 (-0.06, 3.79) |
| Glimepiride | 11 (9, 15) | 0.00 | 1.93 (0.30, 3.54) |
| Pioglitazone | 11 (9, 15) | 0.00 | 1.99 (0.18, 3.84) |
| Rosiglitazone | 13 (9, 16) | 0.02 | 2.94 (0.17, 5.69) |
| Insulin Glargine | 14 (11, 16) | 0.00 | 3.12 (1.47, 4.78) |
| Glibenclamide | 15 (10, 16) | 0.01 | 3.83 (1.25, 6.40) |
| Biphasic Insulin Aspart | 15 (11, 16) | 0.00 | 4.04 (1.49, 6.60) |